Matches in DBpedia 2016-04 for { ?s ?p "Candida krusei is a budding yeast (a species of fungus) involved in chocolate production. Candida krusei is an emerging fungal nosocomial pathogen primarily found in the immunocompromised and those with hematological malignancies. It has natural resistance to fluconazole, a standard antifungal agent. It is most often found in patients who have had prior fluconazole exposure, sparking debate and conflicting evidence as to whether fluconazole should be used prophylactically. Mortality due to C. krusei fungemia is much higher than the more common C. albicans. Other Candida species that also fit this profile are C. parapsilosis, C. glabrata, C. tropicalis, C. guillermondii and C. rugosa. Candida krusei can be successfully treated with voriconazole, amphotericin B, and the echinocandins micafungin, caspofungin, and anidulafungin."@en }
Showing triples 1 to 2 of
2
with 100 triples per page.
- Candida_krusei abstract "Candida krusei is a budding yeast (a species of fungus) involved in chocolate production. Candida krusei is an emerging fungal nosocomial pathogen primarily found in the immunocompromised and those with hematological malignancies. It has natural resistance to fluconazole, a standard antifungal agent. It is most often found in patients who have had prior fluconazole exposure, sparking debate and conflicting evidence as to whether fluconazole should be used prophylactically. Mortality due to C. krusei fungemia is much higher than the more common C. albicans. Other Candida species that also fit this profile are C. parapsilosis, C. glabrata, C. tropicalis, C. guillermondii and C. rugosa. Candida krusei can be successfully treated with voriconazole, amphotericin B, and the echinocandins micafungin, caspofungin, and anidulafungin.".
- Q289229 abstract "Candida krusei is a budding yeast (a species of fungus) involved in chocolate production. Candida krusei is an emerging fungal nosocomial pathogen primarily found in the immunocompromised and those with hematological malignancies. It has natural resistance to fluconazole, a standard antifungal agent. It is most often found in patients who have had prior fluconazole exposure, sparking debate and conflicting evidence as to whether fluconazole should be used prophylactically. Mortality due to C. krusei fungemia is much higher than the more common C. albicans. Other Candida species that also fit this profile are C. parapsilosis, C. glabrata, C. tropicalis, C. guillermondii and C. rugosa. Candida krusei can be successfully treated with voriconazole, amphotericin B, and the echinocandins micafungin, caspofungin, and anidulafungin.".